Image7_Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2.TIFF
In 2019, the novel highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak rapidly led to a global pandemic with more than 346 million confirmed cases worldwide, resulting in 5.5 million associated deaths (January 2022). Entry of all SARS-CoV-2 variants is mediated by the cellular angisin-converting enzyme 2 (ACE2). The virus abundantly replicates in the epithelia of the upper respiratory tract. Beyond vaccines for immunization, there is an imminent need for novel treatment options in COVID-19 patients. So far, only a few drugs have found their way into the clinics, often with modest success. Specific gene silencing based on small interfering RNA (siRNA) has emerged as a promising strategy for therapeutic intervention, preventing/limiting SARS-CoV-2 entry into host cells or interfering with viral replication. Here, we pursued both strategies. We designed and screened nine siRNAs (siA1-9) targeting the viral entry receptor ACE2. SiA1, (siRNA against exon1 of ACE2 mRNA) was most efficient, with up to 90% knockdown of the ACE2 mRNA and protein for at least six days. In vitro, siA1 application was found to protect Vero E6 and Huh-7 cells from infection with SARS-CoV-2 with an up to ∼92% reduction of the viral burden indicating that the treatment targets both the endosomal and the viral entry at the cytoplasmic membrane. Since the RNA-encoded genome makes SARS-CoV-2 vulnerable to RNA interference (RNAi), we designed and analysed eight siRNAs (siV1-8) directly targeting the Orf1a/b region of the SARS-CoV-2 RNA genome, encoding for non-structural proteins (nsp). As a significant hallmark of this study, we identified siV1 (siRNA against leader protein of SARS-CoV-2), which targets the nsp1-encoding sequence (a.k.a. ‘host shutoff factor’) as particularly efficient. SiV1 inhibited SARS-CoV-2 replication in Vero E6 or Huh-7 cells by more than 99% or 97%, respectively. It neither led to toxic effects nor induced type I or III interferon production. Of note, sequence analyses revealed the target sequence of siV1 to be highly conserved in SARS-CoV-2 variants. Thus, our results identify the direct targeting of the viral RNA genome (ORF1a/b) by siRNAs as highly efficient and introduce siV1 as a particularly promising drug candidate for therapeutic intervention.
History
References
- https://doi.org//10.1056/nejmoa2035389
- https://doi.org//10.1038/nm1280
- https://doi.org//10.1056/nejmoa2007764
- https://doi.org//10.1186/1471-2180-1-34
- https://doi.org//10.1016/j.cell.2020.04.026
- https://doi.org//10.1016/j.cmi.2021.05.022
- https://doi.org//10.1038/d41586-021-03552-w
- https://doi.org//10.1021/acs.jcim.1c01451
- https://doi.org//10.1007/s11154-021-09663-z
- https://doi.org//10.1186/s12859-016-0930-z
- https://doi.org//10.1128/jvi.01565-06
- https://doi.org//10.1073/pnas.0912186107
- https://doi.org//10.1161/01.res.87.5.e1
- https://doi.org//10.2807/1560-7917.ES.2021.26.17.2100420
- https://doi.org//10.1073/pnas.0437841100
- https://doi.org//10.1073/pnas.0402486101
- https://doi.org//10.17179/excli2020-1328
- https://doi.org//10.1172/jci16980
- https://doi.org//10.1016/j.it.2020.10.004
- https://doi.org//10.1002/mco2.110
- https://doi.org//10.1016/j.antiviral.2008.10.004
- https://doi.org//10.1038/s41586-020-2368-8
- https://doi.org//10.1016/j.ymthe.2021.05.004
- https://doi.org//10.1186/s12967-021-02840-3
- https://doi.org//10.1016/j.cell.2020.07.033
- https://doi.org//10.1177/15353702211014146
- https://doi.org//10.3389/fphar.2021.616993
- https://doi.org//10.1111/all.14850
- https://doi.org//10.3389/fmicb.2021.758948
- https://doi.org//10.7883/yoken1952.36.17
- https://doi.org//10.15252/embj.2021107821
- https://doi.org//10.1038/nm1267
- https://doi.org//10.1038/sj.gt.3302479
- https://doi.org//10.1038/s41591-020-1088-9
- https://doi.org//10.1016/s0140-6736(20)31866-3
- https://doi.org//10.1056/nejmoa2108891
- https://doi.org//10.1101/2021.08.15.21262077
- https://doi.org//10.1038/nrg908
- https://doi.org//10.1038/s41598-021-88310-8
- https://doi.org//10.1002/adhm.202001650
- https://doi.org//10.3389/fmicb.2020.587317
- https://doi.org//10.15252/msb.20209841
- https://doi.org//10.1016/j.bbrc.2004.07.060
- https://doi.org//10.1056/NEJMoa2023184
- https://doi.org//10.3390/molecules21091249
- https://doi.org//10.1080/22221751.2021.1913973
- https://doi.org//10.3390/cells9051267
- https://doi.org//10.1056/nejmoa2101544
- https://doi.org//10.1111/cbdd.13978
- https://doi.org//10.1021/acs.molpharmaceut.0c01239
- https://doi.org//10.1038/s41564-020-00846-z
- https://doi.org//10.1038/s41594-020-0511-8
- https://doi.org//10.1038/sj.cr.7290286
- https://doi.org//10.1136/bmj.m1256
- https://doi.org//10.1038/s41586-020-2294-9
- https://doi.org//10.1155/2012/256294
- https://doi.org//10.3390/v13102030
- https://doi.org//10.1073/pnas.0402630101
- https://doi.org//10.3389/fbioe.2020.00916
- https://doi.org//10.1038/s41579-020-00468-6
- https://doi.org//10.1016/s0140-6736(21)00976-4
- https://doi.org//10.1126/science.373.6557.838
- https://doi.org//10.1007/s12250-020-00221-6
- https://doi.org//10.7554/eLife.61312
- https://doi.org//10.1038/s41586-020-2196-x
- https://doi.org//10.7150/ijbs.59151
- https://doi.org//10.1016/j.antiviral.2004.09.005
- https://doi.org//10.1038/s41586-020-2008-3
- https://doi.org//10.1038/nm1174
- https://doi.org//10.1128/JVI.01557-08
- https://doi.org//10.16288/j.yczz.20-030
- https://doi.org//10.1016/j.cell.2020.04.035
- https://doi.org//10.1038/s41598-021-85049-0
Usage metrics
Read the peer-reviewed publication
Categories
- Agricultural Marine Biotechnology
- Biomaterials
- Biomechanical Engineering
- Biotechnology
- Biomarkers
- Biomedical Engineering not elsewhere classified
- Synthetic Biology
- Bioremediation
- Bioprocessing, Bioproduction and Bioproducts
- Industrial Biotechnology Diagnostics (incl. Biosensors)
- Industrial Microbiology (incl. Biofeedstocks)
- Industrial Molecular Engineering of Nucleic Acids and Proteins
- Industrial Biotechnology not elsewhere classified
- Medical Biotechnology Diagnostics (incl. Biosensors)
- Biological Engineering
- Medical Molecular Engineering of Nucleic Acids and Proteins
- Regenerative Medicine (incl. Stem Cells and Tissue Engineering)
- Medical Biotechnology not elsewhere classified
- Genetic Engineering